Teduglutide

Generic Name: Teduglutide

Brand Names: Gattex, Revestive

Drug Type: Biotech

CAS Number: 197922-42-2

Unique Ingredient Identifier: 7M19191IKG

Background: Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.

Indication: Teduglutide is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.

Associated Conditions: Short Bowel Syndrome (SBS)

Clinical Trials

A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

Phase 3

Not yet recruiting

Conditions: Short Bowel Syndrome

Interventions: Drug: Teduglutide

First Posted Date: 2025-05-15

Last Posted Date: 2025-05-15

Lead Sponsor: Takeda

Target Recruit Count: 13

Registration Number: NCT06973304

Locations: 🇨🇳
Beijing Tsinghua Changgung Hospital, Changping, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Dongcheng, Beijing, China
🇨🇳
The General Hospital of Eastern Theater Command, Nanjing, Jiangsu, China

and more 1 locations

A Study of PJ009 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Short Bowel Syndrome

Interventions: Drug: PJ009
Drug: Placebo

First Posted Date: 2024-07-26

Last Posted Date: 2024-07-29

Lead Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT06523101

Locations: 🇨🇳
The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China

Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition

Phase 3

Recruiting

Conditions: Short Bowel Syndrome

Interventions: Drug: PJ009 Placebo
Drug: PJ009

First Posted Date: 2024-07-22

Last Posted Date: 2024-08-21

Lead Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.

Target Recruit Count: 72

Registration Number: NCT06512584

Locations: 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
🇨🇳
Chongqing General Hospital, Chongqing, Chongqing, China
🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

and more 5 locations

A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older

Phase 3

Completed

Conditions: Short Bowel Syndrome

Interventions: Drug: Teduglutide

First Posted Date: 2021-08-30

Last Posted Date: 2024-05-16

Lead Sponsor: Takeda

Target Recruit Count: 3

Registration Number: NCT05027308

Locations: 🇯🇵
University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan
🇯🇵
Kagoshiha University Hospital, Kagoshima, Japan
🇯🇵
Tohoku University Hospital, Sendai, Miyagi, Japan

and more 3 locations